Related Experiment Videos
Hyperhomocysteinemia: genetic determinants and selected mouse models.
1Division of Medical Genetics, McGill University Health Centre-Royal Victoria Hospital, Montréal, Que. brian.gilfix@mcgill.ca
Summary
Mild hyperhomocysteinemia, linked to cardiovascular disease and cancer, is common. This review explores genetic factors and mouse models that influence homocysteine levels, aiding disease prevention strategies.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Pathways
Background:
- Homocysteine, a metabolite in the methionine pathway, is associated with cardiovascular disease and cancer.
- Severe hyperhomocysteinemia is rare, but mild elevations are prevalent and linked to increased disease incidence.
- Genetic factors, including gene polymorphisms, significantly influence homocysteine levels.
Purpose of the Study:
- To review the role of common gene polymorphisms in regulating total plasma homocysteine levels.
- To discuss the utility of mouse genetic models in understanding homocysteine metabolism.
- To explore how genetic variations contribute to homocysteine-related pathologies.
Main Methods:
- Literature review focusing on genetic polymorphisms affecting homocysteine.
- Analysis of data from mouse models investigating homocysteine determinants.
- Synthesis of findings on genetic control of homocysteine levels.
Main Results:
- Common gene polymorphisms are key determinants of mild hyperhomocysteinemia.
- Mouse models provide valuable insights into the genetic regulation of homocysteine.
- Understanding these genetic factors is crucial for disease risk assessment.
Conclusions:
- Genetic variations play a significant role in controlling homocysteine levels.
- Investigating polymorphisms and mouse models enhances our understanding of homocysteine's role in disease.
- This knowledge can inform strategies for managing hyperhomocysteinemia and related conditions.